Maintenance Therapy for First-Line Metastatic Colorectal Cancer: Activity and Sustainability

Por Strickler, John H., Hurwitz, Herbert I.
Publicado em 2012

Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

Por Strickler, John H., Hurwitz, Herbert I.
Publicado em 2012

Anti-VEGF Therapies in the Clinic

Por Meadows, Kellen L., Hurwitz, Herbert I.
Publicado em 2012

Understanding and targeting resistance to anti-angiogenic therapies

Por Clarke, Jeffrey M., Hurwitz, Herbert I.
Publicado em 2013

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

Por Liu, Yingmiao, Tian, Hongyu, Blobe, Gerard C., Theuer, Charles P., Hurwitz, Herbert I., Nixon, Andrew B.
Publicado em 2014

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies

Por Cassidy, James, Saltz, Leonard B., Giantonio, Bruce J., Kabbinavar, Fairooz F., Hurwitz, Herbert I., Rohr, Ulrich-Peter
Publicado em 2009

Dual Inhibition of AlphaV Integrins and Src Kinase Activity as A Combination Therapy Strategy for Colorectal Cancer

Por Jia, Jingquan, Starodub, Alex, Cushman, Ian, Liu, Yingmiao, Marshall, Deborah J., Hurwitz, Herbert I., Nixon, Andrew B.
Publicado em 2013

Treatment of Palmar Plantar Erythrodysesthesia (PPE) with Topical Sildenafil: A Pilot Study

Por Meadows, Kellen L., Rushing, Christel, Honeycutt, Wanda, Latta, Kenneth, Howard, Leigh, Arrowood, Christy A., Niedzwiecki, Donna, Hurwitz, Herbert I.
Publicado no Support Care Cancer (2014)

Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials

Por Hurwitz, Herbert I., Tebbutt, Niall C., Kabbinavar, Fairooz, Giantonio, Bruce J., Guan, Zhong-Zhen, Mitchell, Lada, Waterkamp, Daniel, Tabernero, Josep
Publicado em 2013

Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies

Por Hurwitz, Herbert I., Douglas, Pamela S., Middleton, John P., Sledge, George W., Johnson, David H., Reardon, David A., Chen, Dafeng, Rosen, Oliver
Publicado em 2013

Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden

Por Langman, Eun L., Suhocki, Paul V., Hurwitz, Herbert I., Morse, Michael A., Burbridge, Rebecca A., Smith, Tony P., Kim, Charles Y.
Publicado no J Gastrointest Oncol (2016)

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

Por Liu, Yingmiao, Starr, Mark D, Bulusu, Anuradha, Pang, Herbert, Wong, Nan Soon, Honeycutt, Wanda, Amara, Anthony, Hurwitz, Herbert I, Nixon, Andrew B
Publicado em 2013

A Phase II Study of Oxaliplatin, Dose-Intense Capecitabine and High-Dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer

Por Wong, Nan Soon, Fernando, Nishan H., Bendell, Johanna C., Morse, Michael A., Blobe, Gerard C., Honeycutt, Wanda, Pang, Herbert, Hurwitz, Herbert I.
Publicado em 2011

Research Participants' High Expectations of Benefit in Early-Phase Oncology Trials: Are We Asking the Right Question?

Por Weinfurt, Kevin P., Seils, Damon M., Lin, Li, Sulmasy, Daniel P., Astrow, Alan B., Hurwitz, Herbert I., Cohen, Roger B., Meropol, Neal J.
Publicado em 2012

Phase I Dose Escalation Study of Gemcitabine plus Irinotecan in Advanced Solid Tumors

Por Dugan, Elizabeth, Truax, Roxanne, Meadows, Kellen L., Blobe, Gerard C., Morse, Michael A., Fernando, Nishan H., Gockerman, Jon P., Petros, William P., Hurwitz, Herbert I.
Publicado em 2009

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer

Por Liu, Yingmiao, Starr, Mark D, Brady, John C, Dellinger, Andrew, Pang, Herbert, Adams, Bonne, Theuer, Charles P, Lee, Nam Y, Hurwitz, Herbert I, Nixon, Andrew B
Publicado em 2014

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

Por Nixon, Andrew B., Pang, Herbert, Starr, Mark D., Friedman, Paula N., Bertagnolli, Monica M., Kindler, Hedy L., Goldberg, Richard M., Venook, Alan P., Hurwitz, Herbert I.
Publicado no Clin Cancer Res (2013)

Direct Evidence of Target Inhibition with anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing

Por Jia, Jingquan, Dellinger, Andrew E., Weiss, Eric S., Bulusu, Anuradha, Rushing, Christel, Li, Haiyan, Howard, Leigh A., Kaplan, Neal, Pang, Herbert, Hurwitz, Herbert I., Nixon, Andrew B.
Publicado no Clin Cancer Res (2015)

Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)

Por Cushman, Stephanie M., Jiang, Chen, Hatch, Ace J., Shterev, Ivo, Sibley, Alexander B., Niedzwiecki, Donna, Venook, Alan P., Owzar, Kouros, Hurwitz, Herbert I., Nixon, Andrew B.
Publicado no Clin Cancer Res (2014)

A Phase I Dose-Escalation Study of Imatinib Mesylate (Gleevec/STI571) plus Capecitabine (Xeloda) in Advanced Solid Tumors

Por Dugan, Elizabeth, Truax, Roxanne, Meadows, Kellen L., Nixon, Andrew B., Petros, William P., Favaro, Justin, Fernando, Nishan H., Morse, Michael A., Blobe, Gerard C., Hurwitz, Herbert I.
Publicado em 2010